Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.1 million.

  • Voyager Therapeutics' Accounts Payables fell 3303.8% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 3303.8%. This contributed to the annual value of $4.0 million for FY2024, which is 14912.72% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Accounts Payables stood at $2.1 million, which was down 3303.8% from $1.8 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Accounts Payables high stood at $7.6 million for Q1 2024, and its period low was $574000.0 during Q4 2021.
  • In the last 5 years, Voyager Therapeutics' Accounts Payables had a median value of $2.1 million in 2025 and averaged $2.4 million.
  • In the last 5 years, Voyager Therapeutics' Accounts Payables tumbled by 8251.62% in 2021 and then surged by 34703.83% in 2022.
  • Voyager Therapeutics' Accounts Payables (Quarter) stood at $574000.0 in 2021, then skyrocketed by 347.04% to $2.6 million in 2022, then plummeted by 37.49% to $1.6 million in 2023, then soared by 149.13% to $4.0 million in 2024, then tumbled by 47.05% to $2.1 million in 2025.
  • Its Accounts Payables was $2.1 million in Q3 2025, compared to $1.8 million in Q2 2025 and $2.6 million in Q1 2025.